Banned in Himachal, YL Pharma Under Rajasthan Scanner After Spurious Drug Detection

Written By :  Parthika Patel
Published On 2025-11-04 11:00 GMT   |   Update On 2025-11-04 11:00 GMT
Advertisement

Jaipur: In a major revelation, it has emerged that YL Pharma, the pharmaceutical company whose medicines were recently declared spurious in Rajasthan, had already been barred from manufacturing operations in Himachal Pradesh earlier this year, according to state drug regulatory authorities.

The company, YL Pharma, based in Baddi, Himachal Pradesh, had its production activities suspended by the Himachal state government on March 29, according to officials from the Drug Control Office in Dholpur and the state health department.

Advertisement

The matter came to light after a drug sample of Levocetirizine Dihydrochloride tablets (brand name Wincet-L, batch number YLT-25023) manufactured by YL Pharma was collected by the Drug Control Officer in Dholpur. Tests conducted at the Government Analyst Drug Testing Laboratory in Jaipur found the sample to be spurious, prompting immediate action from authorities.

Following the confirmation, the Rajasthan Health Department issued a statewide alert on October 31, notifying all drug controllers about the Himachal government’s suspension of YL Pharma’s licence. The department also launched a sweeping inspection drive across Rajasthan to trace and remove the company’s medicines from the market.

As part of the intensified crackdown, drug control officials inspected 24 pharmaceutical firms across the state. Stocks of Wincet-L tablets were banned, and spurious medicines worth around ₹20 lakh were seized during the raids.

Health Secretary (Health) Gayatri Rathore said that the department has tightened vigilance across manufacturing units and supply chains in light of growing concerns about the quality of medicines being distributed in India. She added that Rajasthan’s drug regulatory teams are conducting regular inspections to ensure patient safety and compliance with drug manufacturing norms.

According to a recent media report by The Times of India, authorities have emphasized that stringent action will continue against firms found violating drug safety standards.

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News